Luigi Mansi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1561029/publications.pdf

Version: 2024-02-01

186254 197805 2,809 115 28 49 citations h-index g-index papers 215 215 215 3197 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	From the Magic Bullet to Theragnostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin Model. Cancers, 2021, 13, 3474.	3.7	3
2	The alleviating effect of herniarin against ionizing radiation-induced genotoxicity and cytotoxicity in human peripheral blood lymphocytes. Current Radiopharmaceuticals, 2021, 14, .	0.8	1
3	The Multicenter Italian Trial Assesses the Performance of FDG-PET /CT Related to Pre-Test Cancer Risk in Patients with Solitary Pulmo n ary Nodules and Introduces a Segmental Thoracic Diagnostic Strategy. Current Radiopharmaceuticals, 2020, 13, 243-248.	0.8	3
4	99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other) Tj ETQq0 0) 0 rgBT /O	verlock 10 Tf
5	Radiolabeled somatostatin analogues for the diagnosis and therapy of NETs: upcoming new strategies. Clinical and Translational Imaging, 2020, 8, 21-27.	2.1	0
6	The Screening of Renoprotective Agents by 99mTc-DMSA: A Review of Preclinical Studies. Current Radiopharmaceuticals, 2019, 12, 211-219.	0.8	2
7	Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours. Current Radiopharmaceuticals, 2019, 12, 98-106.	0.8	10
8	Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?. Current Radiopharmaceuticals, 2019, 12, 156-170.	0.8	16
9	Will 68 Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.2	0
10	Preliminary Human Radiation Dose Estimates of PET Renal Agents, Para-18F-Fluorohippuric Acid and Ortho-124I-lodohippuric Acid from Rat Biodistribution Data. Current Radiopharmaceuticals, 2018, 11, 58-63.	0.8	2
11	Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1898-1907.	6.4	17
12	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1908-1914.	6.4	12
13	Nuclear medicine in prostate cancer: A new era for radiotracers. World Journal of Nuclear Medicine, 2018, 17, 70.	0.5	26
14	The delicate balance between present and future. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 346-347.	6.4	2
15	Pitfalls and artifacts of FDG PET/CT in recurrent breast cancer patients. Clinical and Translational Imaging, 2017, 5, 169-182.	2.1	0
16	The natural history of takotsubo syndrome: a two-year follow-up study with myocardial sympathetic and perfusion G-SPECT imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 267-283.	6.4	13
17	Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. International Journal of Oncology, 2017, 51, 281-288.	3.3	52
18	Molecular Imaging of Huntington's Disease. Journal of Cellular Physiology, 2017, 232, 1988-1993.	4.1	6

#	Article	IF	Citations
19	Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1-4.	6.4	29
20	Biochemical and Pathophysiological Premises to Positron Emission Tomography With Choline Radiotracers. Journal of Cellular Physiology, 2017, 232, 270-275.	4.1	28
21	Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?. Indian Journal of Radiology and Imaging, 2017, 27, 509-516.	0.8	8
22	Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs. Nuclear Medicine Review, 2017, 20, 49-56.	0.5	24
23	Contrast-Enhanced Ultrasound in the Assessment of Patients with Indeterminate Abdominal Findings at Positron Emission Tomography Imaging. Ultrasound in Medicine and Biology, 2016, 42, 2717-2723.	1.5	7
24	Pediatric molecular imaging today: new technologies, new challenges, new answers. Clinical and Translational Imaging, 2016, 4, 75-77.	2.1	1
25	Effects of α-lipoic acid therapy on sympathetic heart innervation in patients with previous experience of transient takotsubo cardiomyopathy. Journal of Cardiology, 2016, 67, 153-161.	1.9	55
26	Diagnostic Imaging and Pathology. Current Clinical Pathology, 2016, , 107-111.	0.0	1
27	Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT. Current Radiopharmaceuticals, 2016, 9, 103-113.	0.8	13
28	Peculiar Aspects and Problems of Diagnostic Nuclear Medicine in Paediatrics., 2016,, 1-18.		0
29	SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer. Current Radiopharmaceuticals, 2015, 8, 9-18.	0.8	3
30	18F-fluoromethylcholine or 18F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. Nuclear Medicine and Biology, 2015, 42, 340-348.	0.6	25
31	Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement. Journal of Ultrasound, 2015, 18, 423-430.	1.3	104
32	Diagnostic Imaging in Neuroendocrine Tumors. Journal of Nuclear Medicine, 2014, 55, 1576-1577.	5.0	16
33	Role of PET and SPECT in the Study of Amyotrophic Lateral Sclerosis. BioMed Research International, 2014, 2014, 1-7.	1.9	24
34	Is Radiocholine PET/CT Already Clinically Useful in Patients with Prostate Cancer?. Journal of Nuclear Medicine, 2014, 55, 1401-1403.	5.0	15
35	"The quantification with FDG as seen by a physician.―Nucl Med Biol 2013;40:720–30. Nuclear Medicine and Biology, 2014, 41, 611-612.	0.6	0
36	Perspectives on PET/MR Imaging: Are We Ready for Clinical Use?. Journal of Nuclear Medicine, 2014, 55, 529-530.	5.0	10

#	Article	lF	CITATIONS
37	From Homo sapiens to Homo in nexu (connected man): could functional imaging redefine the brain of a "new human species�. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1385-1387.	6.4	6
38	18FNa-fluoride has a higher extraction with respect to 99mTc-methylene diphosphonate: Mismatch in a case of meningioma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2014, 33, 52-53.	0.0	2
39	Editorial Review of 2014. Current Radiopharmaceuticals, 2014, 7, 1-4.	0.8	1
40	Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: Effects on myocardial salvage. International Journal of Cardiology, 2013, 168, 3954-3962.	1.7	62
41	The quantification with FDG as seen by a physician. Nuclear Medicine and Biology, 2013, 40, 720-730.	0.6	17
42	Molecular pathways and molecular imaging in breast cancer: An update. Nuclear Medicine and Biology, 2013, 40, 581-591.	0.6	14
43	Weighted registration of ¹²³ <scp>I</scp> â€ <scp>FP</scp> â€CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake. Journal of Cellular Physiology, 2013, 228, 2086-2094.	4.1	7
44	Bone Metastases Radiopharmaceuticals: An Overview. Current Radiopharmaceuticals, 2013, 6, 41-47.	0.8	54
45	Peptide Imaging with Somatostatin Analogues: More than Cancer Probes. Current Radiopharmaceuticals, 2013, 6, 36-40.	0.8	35
46	Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer. Current Radiopharmaceuticals, 2013, 6, 57-71.	0.8	36
47	Neurological applications for myocardial MIBG scintigraphy. Nuclear Medicine Review, 2013, 16, 35-41.	0.5	22
48	Crohn's Disease Imaging: A Review. Gastroenterology Research and Practice, 2012, 2012, 1-15.	1.5	34
49	PET/MRI and the revolution of the third eye. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1519-1524.	6.4	35
50	Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1262-1265.	6.4	20
51	Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism. Journal of Cellular Physiology, 2012, 227, 1663-1669.	4.1	0
52	Nuclear medicine is to Fukushima as drug is to poison: El sue $\tilde{A}\pm 0$ de la raz \tilde{A}^3 n produce monstruos. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 369-372.	6.4	4
53	Myocardial perfusion imaging and risk classification for coronary heart disease in diabetic patients. The IDIS study: a prospective, multicentre trial. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 387-395.	6.4	38
54	Diagnosis and therapy are walking together on radiopeptides' avenue. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 605-612.	6.4	19

#	Article	IF	CITATIONS
55	Time for radiobiology in the nuclear medicine community. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1267-1269.	6.4	4
56	Inflammatory bowel disease: value in diagnosis and management of MDCT-enteroclysis and 99mTc-HMPAO labeled leukocyte scintigraphy. Abdominal Imaging, 2011, 36, 372-381.	2.0	20
57	PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. Journal of Cellular Physiology, 2011, 226, 948-961.	4.1	16
58	The role of Tc-99m-2-Methoxy-Isobutyl-Isonitrile Single Photon Emission Computed Tomography in visualizing anterior mediastinal tumor and differentiating histologic type of thymoma. European Journal of Cardio-thoracic Surgery, 2011, 40, 136-142.	1.4	14
59	Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 12-22.	6.4	2
60	The new FDG brain revolution: the neurovascular unit and the default network. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 913-916.	6.4	14
61	Direct imaging of viable myocardium by gated SPECT in patients with ischaemic left ventricular dysfunction. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1730-1735.	6.4	5
62	Our experience in thymic hyperplasia using 67Ga-citrate, 111In-pentetreotide and 201Tl-chloride. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1616-1616.	6.4	3
63	Imaging of cell trafficking in Crohn's disease. Journal of Cellular Physiology, 2010, 223, 562-571.	4.1	25
64	Rosiglitazone and Cognitive Stability in Older Individuals With Type 2 Diabetes and Mild Cognitive Impairment. Diabetes Care, 2010, 33, 1706-1711.	8.6	78
65	F-18-2-Fluoro-2-Deoxyglucose Positron Emission Tomography Compared to Technetium-99m Hexakis-2-Methoxyisobutyl Isonitrile Single Photon Emission Chest Tomography in the Diagnosis of Indeterminate Lung Lesions. Respiration, 2010, 80, 524-533.	2.6	7
66	Editorial [Hot Topic: PET – CT AND RADIOTHERAPY (Guest Editors: Diana Salvo, Annibale Versari & ETÇ	90 <mark>0.8</mark> 0 rgl	BT Overlock
67	The role of technetium-99m hexakis-2-methoxyisobutyl isonitrile in the detection of neoplastic lung lesionsâ~†. European Journal of Cardio-thoracic Surgery, 2009, 35, 325-331.	1.4	19
68	Radio-guided surgery for ventricular remodeling in patients with ischemic dilated cardiomyopathy: A new tool to discriminate in vivo viable myocardium and scar. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 241-243.	0.8	1
69	Ich bin ein Molekularmediziner (how much CT and nuclear medicine in molecular CT?). European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 531-532.	6.4	3
70	Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1113-1120.	6.4	52
71	Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology. Current Radiopharmaceuticals, 2009, 2, 224-253.	0.8	37
72	Genitourinary Disorders. , 2009, , 255-318.		0

#	Article	IF	CITATIONS
73	IAEA Technical Report Series. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1030-1031.	6.4	10
74	The absolute (quantitative): dialogue between St. Thomas and Lord Kelvin. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1725-1728.	6.4	3
75	Scintigraphic evaluation of oesophageal transit during radiotherapy to the mediastinum. BMC Gastroenterology, 2008, 8, 51.	2.0	8
76	Administering radioiodine treatment; alternative to nuclear medicine prescribing. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1512-1513.	6.4	1
77	Continuous Monitoring of Left Ventricle Function by VEST in Hemodialyzed Patients. Seminars in Nephrology, 2006, 26, 80-84.	1.6	1
78	Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis. Nuclear Medicine Communications, 2006, 27, 213-222.	1.1	16
79	Permanent renal parenchymal defects after febrile UTI are closely associated with vesicoureteric reflux. Pediatric Nephrology, 2006, 21, 521-526.	1.7	52
80	Surgical treatment of differentiated thyroid carcinoma: a retrospective study. Frontiers in Bioscience - Landmark, 2006, 11, 2206.	3.0	1
81	The Role of Scintigraphy in the Management of Children with Neurogenic Bladder Dysfunction. , 2006, , 123-131.		0
82	Effects of insulin on left ventricular function during dynamic exercise in overweight and obese subjects. European Heart Journal, 2005, 26, 1205-1212.	2.2	17
83	The growing importance of continuing medical education in nuclear medicine: the role of the European School of Nuclear Medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, B23.	6.4	16
84	From the magic bullet to an effective therapy: the peptide experience. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1393-8.	6.4	5
85	A 69-year-old woman with persistent iron deficiency anemia. Annals of Hematology, 2004, 83, 474-476.	1.8	1
86	Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2004, 48, 82-95.	0.7	17
87	FDG-PET in infectious and inflammatory disease. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1568-1570.	6.4	17
88	A Preservation Method That Allows Recovery of Intact RNA from Tissues Dissected by Laser Capture Microdissection. Analytical Biochemistry, 2002, 300, 139-145.	2.4	38
89	Unilateral vesicoureteric reflux: Low prevalence of contralateral renal damage. Journal of Pediatrics, 2001, 138, 875-879.	1.8	9
90	Enhanced detection of vesicoureteric reflux with isotopic cystography. Pediatric Nephrology, 2000, 14, 827-830.	1.7	31

#	Article	IF	Citations
91	Primary vesicoureteric reflux and renal damage in the first year of life. Pediatric Nephrology, 2000, 15, 205-210.	1.7	46
92	HIGH INCIDENCE OF A GENERALLY SMALL KIDNEY AND PRIMARY VESICOURETERAL REFLUX. Journal of Urology, 2000, 164, 479-482.	0.4	48
93	Effects of insulin-glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients. Journal of the American College of Cardiology, 2000, 36, 219-226.	2.8	59
94	Body growth in early diagnosed vesicoureteric reflux. Pediatric Nephrology, 1999, 13, 876-879.	1.7	18
95	Measurement of Glomerular FiltrationRate by the ^{99m} < /sup>Tc-DTPA Renogram Is Less Precise than Measured and Predicted Creatinine Clearance. Nephron, 1999, 81, 136-140.	1.8	47
96	A SIMPLE SIGN FOR THE DIFFERENTIAL DIAGNOSIS OF THE CONGENITAL TRIGGER THUMB. Plastic and Reconstructive Surgery, 1999, 103, 748-749.	1.4	2
97	Intraoperative detection of lung cancer by octreotide labeled to Indium-111. , 1998, 15, 220-222.		7
98	Long-term effects on left ventricular function after late thrombolysis in patients with myocardial infarction. Current Therapeutic Research, 1997, 58, 570-574.	1.2	0
99	High Prevalence of Myocardial Ischemia and Vasoconstrictive Hormonal Release in Hypertension during Chronic Renal Failure. Nephron, 1997, 76, 434-444.	0.6	6
100	99mTc-Tetrofosmin in Breast Cancer: Experience of the Second University of Naples. Tumori, 1997, 83, 523-525.	1.1	0
101	Pheochromocytoma Diagnosed With 1-123 MIBG Scintigraphy in a Patient With Concomitant Bilateral Polycystic Kidneys. Clinical Nuclear Medicine, 1997, 22, 268-270.	1.3	2
102	Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 932-939.	2.1	64
103	Scintimammography with technetium-99m tetrofosmin. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 229-229.	2.1	0
104	Kinetics of Tc-99m Sestamibi and Tc-99m Tetrofosmin in a Case of Parathyroid Adenoma. Clinical Nuclear Medicine, 1996, 21, 700-703.	1.3	13
105	Breast Cancer Detection With Tc-99m Tetrofosmin. Clinical Nuclear Medicine, 1995, 20, 703-705.	1.3	51
106	Radionuclide angiographic evaluation of left ventricular function in hypertensive patients treated with extended-release felodipine. Current Therapeutic Research, 1994, 55, 422-428.	1.2	0
107	Effect of acute administration of -acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct. Pharmacological Research, 1991, 23, 241-246.	7.1	11
108	Mixed Transcortical Aphasia: Clinical Features and Neuroanatomical Correlates. European Neurology, 1991, 31, 204-211.	1.4	25

#	Article	IF	CITATIONS
109	Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 129-132.	2.1	1
110	Diagnosis of ovarian cancer with radiolabelled monoclonal antibodies: Our experience using 131l—B72.3. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1989, 16, 127-135.	0.3	10
111	Simplified, Noninvasive PET Measurement of Blood-Brain Barrier Permeability. Journal of Computer Assisted Tomography, 1987, 11, 390-397.	0.9	70
112	Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Annals of Neurology, 1984, 15, 138-146.	5.3	105
113	Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Annals of Neurology, 1984, 15, 170-174.	5.3	178
114	Cortical abnormalities in Alzheimer's disease. Annals of Neurology, 1984, 16, 649-654.	5.3	369
115	Depressed cerebellar glucose metabolism in supratentorial tumors. Brain Research, 1984, 291, 93-101.	2.2	103